Table 7. CH/SN-EVAR cohort clinical outcome.
| Authors | MAE (major adverse events) | 30-day mortality | Cause of death | Over 30day mortality | Cause of death | Patency (6 months) | Follow-up (months) | Length of stay (days) | Secondary intervention rate |
|---|---|---|---|---|---|---|---|---|---|
| Donas et al. 201231 | 1 MI; 2 Type II endoleaks; 1 RA occlusion; | 0 | N.D. | N.D. | 97.4% | 15.2 ± 6.2 | 3.5 | 3.3% | |
| Suominen et al. 201332 | 1 MI; 4 wound Infection; 1 common ilac artery embolism; 1 Type II endoleak; 2 RFI;1 Renal stent twist | 0 | 3 | 2 M.I. (5 and 7 months) 1 lower limb ischemia | N.D. | 22 (1–46) | N.D. | 25% | |
| Lee et al. 201433 | 3 Type I, 6 Type IIand 1 Type III endoleaks; 19 RFI; | 2 | 2 M.I. | 4 | 4 M.I. | 95% (24 months) | 21.1 (2.6–40.4) | N.D. | 4.7% |
| Schiro et al. 201319 | 1 MI; 1 arrhythmia; 5Type I endoleaks; 1 ARF(need dialysis) | 0 | 2 | 2 AAA rupture (11 and 16 months, caused by type I endoleak) | N.D. | 12 (5–24) | N.D. | 0 | |
| Ducasse et al.201334 | 1 stroke; 1 lower limb embolism; 1Type I; 4Type IIendoleaks; 2 ARF;2 accessory renal artery occlusion | 1 | 1 acute heart disease | 0 | N.D. | 18 (7–35) | 6.5 (4–50) | 9% | |
| Tolenaar et al. 201335 | 1Type I endoleak; 1 RA occlusion | 0 | 2 | 1tumor 1 M.I. (26 months) | 90.9% | 10.87 (m4–19.4) | 4 (3–9.5) | 0 | |
| Lgari et al. 201436 | 1 pneumonia; 1Type II endoleak; | 0 | 0 | 100% | 11 (2–22) | N.D. | 0 | ||
| Banno et al. 201437 | 1 arrhythmia; 1 COPD; 2 bowel ischemia; 1 colitis; 2 cerebral infarction; 8 wound complications; 3 intra-abdominal or retroperitoneal hemorrhage; 1 urinary tract infection; 2Type I; 2Type IIendoleaks; 7 RFI;1 dialysis;2 Renal infract | 3 | 3 bowel ischemia M.O.F. | 4 | Not related to AAA | 95.2% (12 months) | 12 (0–48) | N.D. | 28% |
N.D. not documented; M.I. myocardial infarction; COPD, chronic obstructive pulmonary disease; M.O.F. multiple organ failure; RFI, renal function impairment; ARF, acute renal failure; RF, renal failure; RA, renal artery; SMA, superior mesenteric artery.